OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
03 sep 2008 - 01:11
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus obtains additional 0.75 million euro bridge financing
Bericht
OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO), the drug delivery and development company, announces today that it has received an additional € 0.75 million from its co-development partner Biolex Therapeutics as part of its recently announced bridge financing. The payment by Biolex will expand OctoPlus’ bridge financing to a total of € 6.75 million. The other participants in the bridge financing are OctoPlus’ major shareholders Life Sciences Partners and SR One.
The bridge loan may be converted by each of the lenders for a participation in a potential private offering, or alternatively, in ordinary shares, which will have a dilutive effect. If and when the loan is converted into ordinary shares, these shares will be issued at the higher of € 1.– or a 45% discount to the 10 days average of the then prevailing stock price.
Datum laatste update: 18 maart 2025